Hong Kong Market Pulse: TRANSTHERA-B Soars Over 11% on Phase II Trial Progress and Commercial Launch

Stock News09-21

Shares of TRANSTHERA-B (02617) surged more than 11% in Hong Kong trading on Thursday, with the stock last changing hands at HK$11.17, up 11.37%, on turnover of HK$103 million.

According to a company announcement released on the evening of September 18, the first patient has been dosed in the China Phase II clinical trial evaluating its core product Tinengotinib (Jientai®, TT-00420) in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after prior therapy.

In a separate development on September 17, TRANSTHERA-B announced that the first batch of its core product Jientai® (Tinengotinib tablets) has officially shipped through commercial channels to pharmacies across the country, marking the commencement of nationwide commercial supply. This milestone signifies that the globally first-in-class targeted therapy for cholangiocarcinoma addressing FGFR inhibitor resistance is now poised to reach patients throughout China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143122994?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143122994","market":"other","top_or_hot":-1,"title":"Hong Kong Market Pulse: TRANSTHERA-B Soars Over 11% on Phase II Trial Progress and Commercial Launch","media":"Stock News","content":"<p>Shares of <b>TRANSTHERA-B</b> (<b>02617</b>) surged more than 11% in Hong Kong trading on Thursday, with the stock last changing hands at HK$11.17, up 11.37%, on turnover of HK$103 million.<br><br>According to a company announcement released on the evening of September 18, the first patient has been dosed in the China Phase II clinical trial evaluating its core product Tinengotinib (Jientai®, TT-00420) in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after prior therapy.<br><br>In a separate development on September 17, <b>TRANSTHERA-B</b> announced that the first batch of its core product Jientai® (Tinengotinib tablets) has officially shipped through commercial channels to pharmacies across the country, marking the commencement of nationwide commercial supply. This milestone signifies that the globally first-in-class targeted therapy for cholangiocarcinoma addressing FGFR inhibitor resistance is now poised to reach patients throughout China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Market Pulse: TRANSTHERA-B Soars Over 11% on Phase II Trial Progress and Commercial Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Market Pulse: TRANSTHERA-B Soars Over 11% on Phase II Trial Progress and Commercial Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-21 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>TRANSTHERA-B</b> (<b>02617</b>) surged more than 11% in Hong Kong trading on Thursday, with the stock last changing hands at HK$11.17, up 11.37%, on turnover of HK$103 million.<br><br>According to a company announcement released on the evening of September 18, the first patient has been dosed in the China Phase II clinical trial evaluating its core product Tinengotinib (Jientai®, TT-00420) in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after prior therapy.<br><br>In a separate development on September 17, <b>TRANSTHERA-B</b> announced that the first batch of its core product Jientai® (Tinengotinib tablets) has officially shipped through commercial channels to pharmacies across the country, marking the commencement of nationwide commercial supply. This milestone signifies that the globally first-in-class targeted therapy for cholangiocarcinoma addressing FGFR inhibitor resistance is now poised to reach patients throughout China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1143122994","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143122994","pubTimestamp":1789959135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of TRANSTHERA-B (02617) surged more than 11% in Hong Kong trading on Thursday, with the stock last changing hands at HK$11.17, up 11.37%, on turnover of HK$103 million.According to a company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard"},"translate_title":"香港市场脉搏：TRANSTHERA-B 因 II 期试验进展和商业推出飙升超过 11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"VXUS":1,"KCAI":1},"content_text":"Shares of TRANSTHERA-B (02617) surged more than 11% in Hong Kong trading on Thursday, with the stock last changing hands at HK$11.17, up 11.37%, on turnover of HK$103 million.According to a company announcement released on the evening of September 18, the first patient has been dosed in the China Phase II clinical trial evaluating its core product Tinengotinib (Jientai®, TT-00420) in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after prior therapy.In a separate development on September 17, TRANSTHERA-B announced that the first batch of its core product Jientai® (Tinengotinib tablets) has officially shipped through commercial channels to pharmacies across the country, marking the commencement of nationwide commercial supply. This milestone signifies that the globally first-in-class targeted therapy for cholangiocarcinoma addressing FGFR inhibitor resistance is now poised to reach patients throughout China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143122994","isCrawlerRequest":true}